Company Timeline

Apex AI has been at the forefront of AI-powered gastrointestinal cancer diagnostics, continuously innovating and expanding through strategic partnerships, R&D breakthroughs, and global commercialization efforts.

2024

• Selected for the “TIPS Global Marketing Support Program” (Korea Ministry of SMEs & Startups).

• Chosen for the “Smart Healthcare Technology Program”, further strengthening AI-driven healthcare innovations.

• Signed strategic business partnership agreement with iKooB for joint commercialization efforts.

2023 - 2022

• Successfully completed the TIPS 2nd Year Program & Startup Commercialization Support Project.

• Developed an AI-powered early detection & tracking platform for gastrointestinal cancer risk management.

• Conducted multi-hospital clinical studies with Seoul National University Hospital, Yonsei University Severance Hospital, and five other leading medical centers.

• Completed the CDW (Clinical Data Warehouse) AI System for Predicting Intradialytic Hypotension (IDH).

2021

• Developed and launched an AI-based early detection & tracking system for gastrointestinal cancer risk assessment.

• Selected for the TIPS Core Program, validating its potential for AI-driven clinical applications.

• Completed AI development for Acute Kidney Injury (AKI) prediction.

• Developed new AI-driven diagnostic models for early-stage cancer detection.

• Certified as a Venture Company.

2020 - 2019

• Completed a multi-tiered AI platform for Helicobacter pylori-associated stomach cancer risk assessment.

• Secured Seed investment from healthcare-focused venture capital.

• Selected for Korean government-backed startup acceleration programs, including:

  • Technology commercialization initiative for innovative SMEs.

  • Incheon National University’s AI healthcare R&D project.

• Recognized as the #1 innovation at the 2019 NEMIC (New England Medical Innovation Center) MedTech Bootcamp